On November 23, 2022 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ("Vivoryon" and hereinafter the "Company"), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported that it has successfully completed the listing of 2,054,796 shares issued pursuant to its private placement announced on September 30, 2022 (Press release, Vivoryon Therapeutics, NOV 23, 2022, View Source [SID1234624412]). The private placement was supported by Vivoryon’s longstanding investor Claus Christiansen as well as a platform controlled by affiliates of Kohlberg Kravis Roberts & Co. L.P. ("KKR"), a leading global investment firm, as new investor to the Company (the "Investors").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimer’s disease ("AD") drug development. The Company has demonstrated evidence of the disease modifying capabilities of its lead candidate varoglutamstat, currently in Phase 2 clinical studies in Europe and the U.S.. Underscoring the unique potential of varoglutamstat in mono- and combination therapy settings in AD, data generated to date show the potential for cognitive improvement and a beneficial safety profile at doses of high target engagement.

As previously announced, the Investors agreed to invest an amount of EUR 15.0 million in the Company by purchasing 2,054,796 new ordinary shares at an offering price of EUR 7.30 per share by means of a capital increase from the Company. The new shares issued at the time of the offering represented 9.3% of Vivoryon’s issued share capital immediately prior to completion of the offering and were issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights. As a consequence, the Company’s issued share capital increased to EUR 24,105,278.00.The Company, with support of Van Lanschot Kempen N.V., has now successfully applied for the admission of these new shares to collective safe custody with Nederlands Centraal Instituut voor Giraal Effectenverkeer B.V., trading as Euroclear Nederland as well as to trading on Euronext Amsterdam (the "Listing").

For the Listing, an EU Recovery prospectus has been prepared in accordance with, Article 14a of the Prospectus Regulation (as amended by the Regulation (EU) 2021/337 of the European Parliament and of the Council of 16 February 2021).

In addition, as previously announced, the Investors have the option to purchase, in aggregate, up to another 2,054,796 shares during a period ending twelve months after the date of the approval of the EU Recovery prospectus or three months after the achievement date of a defined clinical milestone, whichever is later, at a price of EUR 7.30 per share.